Zdorovʹe Rebenka (Oct 2018)

Metabolic therapy in children with hypotensive type of autonomic dysfunction syndrome

  • Yu.V. Marushko,
  • T.V. Hyshchak

DOI
https://doi.org/10.22141/2224-0551.13.7.2018.148920
Journal volume & issue
Vol. 13, no. 7
pp. 666 – 673

Abstract

Read online

Background. Trimetabol is a combined appetite stimulant that has cardioprotective, neurotropic and antioxidant effects. The purpose was to evaluate the effectiveness of metabolic therapy with the use of Trimetabol in children with hypotensive type of autonomic dysfunction syndrome. Materials and methods. Forty five children aged 9–17 years with autonomic hypotensive dysfunction were examined. All children were divided into two groups: the main group (n = 30) received Trimetabol, the comparison group (n = 15) — multivitamins. The course of treatment was 1 month. Results. Against the background of treatment with Trimetabol, headache, dizziness, heart pain decreased, appetite, heart rhythm and conduction normalized. Unlike the comparison group, the children of the main group experienced better dynamics of ambulatory blood pressure monitoring (ABPM) and heart rate variability. According to ABPM, average daily systolic blood pressure (SBP) increased from 107.4 ± 1.0 mmHg to 110.8 ± 1.1 mmHg, p < 0.05 (in the comparison group, it has not changed significantly), the time index of hypotension of SBP decreased from 36.3 ± 2.9 % to 25.4 ± 2.6 %, p < 0.01 (in the comparison group — from 40.7 ± 4.7 % to 26.8 ± 4.6 %, p < 0.05). Reduction in total spectrum power was observed in both groups, but in the main group, it was more significant and occurred as a result of a decrease in VLF% (from 75.82 ± 1.63 % to 69.50 ± 1.70 %, p < 0.05), and due to an increase in the specific gravity of LF (from 8.78 ± 0.43 % to 10.20 ± 0.37 %, p < 0.05) and HF% (from 11.31 ± 0.46 % to 13.90 ± 0.80 %, p < 0.05). These data indicate that under the influence of Trimetabol, the central and autonomic regulation circuit activity was redistributed from the decrease in the activity of the central circuits (VLF%) and the relative increase in the activity of autonomic circuits (LF%, HF%). Conclusions. Trimetabol is an effective drug for the treatment of hypotensive type of autonomic dysfunction. The use of Trimetabol improves metabolic processes in the myocardium, normalizes the autonomic regulation of the cardiac rhythm and blood pressure and is safe for adolescents.

Keywords